Immuneering Corporation
IMRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -84.8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | 50.1% | 44.6% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -16,238.4% | -1,621.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -15,937.3% | -1,612.3% |
| EPS Diluted | -2.04 | -1.88 | -1.87 | -1.27 |
| % Growth | -8.5% | -0.5% | -47.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |